Growth • EyePoint Pharmaceuticals
EYPT
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
4,2%
CAGR Revenue 5Y
Revenue Compound Annual Growth Rate in the last 5 years.
42,4%
CAGR Op. Income 5Y
Operating Income Compound Annual Growth Rate in the last 5 years.
35,3%
CAGR Net Income 5Y
Net Income Compound Annual Growth Rate in the last 5 years.
-3,3%
CAGR EPS 5Y
Earnings Per Share Compound Annual Growth Rate in the last 5 years.
71%
CAGR OCF 5Y
Cash Flow from Operating activities Compound Annual Growth Rate in the last 5 years.
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!